The BD CTGCTV2 assay is a 3-in-1 FDA-cleared test designed to detect the 3 most prevalent non-viral sexually transmitted infections simultaneously and separately.1-5
BD CTGCTV2 provides reliable results with high sensitivity and specificity to support informed clinical decision-making.2-5
BD CTGCTV2 assay: Flexibility in STI testing
CDC, Centers for Disease Control and Prevention; CT, Chlamydia trachomatis; FDA, Food and Drug Administration; GC, Neisseria gonorrhoeae; NAAT, nucleic acid amplification test; STI, sexually transmitted infection; TV, Trichomonas vaginalis.
1. Sexually Transmitted Infections Prevalence, Incidence, and Cost Estimates in the United States, CDC. 2021. Accessed 29 Apr 2022.
2. BD CTGCTV2 for BD MAX™ System Package Insert [P0237].
3. Van Der Pol B et al. Sex Transm Dis. 2021;48(2):134–40.
4. Workowski KA et al. MMWR Recomm Rep. 2021;70(4):1–187.
5. Chlamydia – CDC Fact Sheet, CDC. 2022. Accessed 10 Apr 2022.
Learn more about our BD Women’s Health solutions
This form is only intended for use by healthcare professionals seeking additional information about BD products and solutions. Patients seeking health and treatment information should contact their healthcare professional and can find additional resources from ACOG and the American Cancer Society.
Do not submit protected health information (PHI) or patient information (PII) through this form. If you do submit PHI or PII, your question may not be answered, as the information will be deleted to protect your privacy.